PT-141 (Bremelanotide) Dosage Guide
Gender-specific protocols for PT-141 — FDA-approved dosing for women, off-label protocols for men, reconstitution, injection technique, frequency limits, and safety.
In This Guide
What Is PT-141?
PT-141 (Bremelanotide) is one of only two peptides in this guide that is FDA-approved — its approval is for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi. Unlike PDE5 inhibitors (Viagra, Cialis) that work on blood flow, PT-141 works centrally in the brain through melanocortin receptors to enhance sexual desire and arousal.
PT-141 is a cyclic heptapeptide analog of alpha-MSH. It acts as an agonist at melanocortin-4 receptors (MC4R) in the hypothalamus. What makes PT-141 dosing unique is the gender-specific approach and strict frequency limitations. The FDA label caps use at 8 doses per month.
Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.
Key Characteristics:
- Central mechanism — works in the brain, not on blood vessels — fundamentally different from Viagra/Cialis
- MC4R agonist — activates melanocortin-4 receptors (MC4R) in the hypothalamus to enhance sexual desire and arousal
- Both genders — studied in both men and women, but FDA-approved only for premenopausal women with HSDD
- As-needed dosing — not taken daily — administered 45+ minutes before anticipated sexual activity
- Frequency limit — maximum 8 doses per month, no more than 1 dose per 24 hours
- Injectable or nasal — SubQ injection (FDA-approved route) or nasal spray (research)
- Derived from Melanotan II — structurally modified to focus on sexual function with reduced tanning effects
Clinical Trials:
- RECONNECT trials — two Phase 3 randomized, placebo-controlled trials in premenopausal women with HSDD (n=1,247). 1.75 mg SubQ showed statistically significant improvement in sexual desire and reduction in distress
- Male erectile dysfunction studies — Phase 2 trials demonstrated efficacy at 1–2 mg doses, including in men who did not respond to sildenafil (Viagra)
For a complete overview of its mechanism and research, see our full PT-141 profile. New to peptides? Start with the Beginner's Guide to Peptides.
PT-141 Dosage: Women (FDA-Approved)
The following protocol reflects the FDA-approved Vyleesi prescribing information for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). This is the only FDA-approved use of PT-141.
| Parameter | Protocol |
|---|---|
| Dose | 1.75 mg SubQ |
| Timing | At least 45 minutes before anticipated sexual activity |
| Maximum per day | 1 dose per 24 hours |
| Monthly limit | 8 doses per month |
| Onset | 45–60 minutes |
| Duration | 4–6+ hours |
PT-141 Dosage: Men (Off-Label)
PT-141 has been studied in men for erectile dysfunction in Phase 2 clinical trials. It demonstrated efficacy at 1–2 mg doses, including in men who did not respond to PDE5 inhibitors (Viagra, Cialis). Male use of PT-141 is entirely off-label.
| Parameter | Protocol |
|---|---|
| Dose | 1.0–2.0 mg SubQ |
| Timing | 1–2 hours before anticipated sexual activity |
| Maximum per day | 1 dose per 24 hours |
| Monthly limit | 8–10 doses per month |
| Onset | 1–2 hours (slower than women) |
| Duration | 4–6+ hours |
Verified sources for PT-141
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Calculate Your PT-141 Dose
PT-141 is available as Vyleesi (pre-filled auto-injector) or as a compounded lyophilized (freeze-dried) powder, typically in 10 mg vials. For compounded vials, you reconstitute with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.
Worked Example:
- Vial size: 10 mg (10,000 mcg) of PT-141
- Bacteriostatic water added: 2 mL
- Concentration: 10 mg ÷ 2 mL = 5 mg per mL
- Target dose: 1.75 mg
- Volume to draw: 1.75 ÷ 5 = 0.35 mL = 35 units on an insulin syringe
Quick Reference — 10 mg Vial
| Bac Water Added | Concentration | 1.75 mg Dose | Doses per Vial |
|---|---|---|---|
| 2 mL | 5 mg/mL | 35 units (0.35 mL) | ~5 doses |
| 5 mL | 2 mg/mL | 87.5 units (0.875 mL) | ~5 doses |
Calculate Your PT-141 Dose Instantly
Enter your PT-141 vial size, water volume, and desired dose — get instant calculations with zero manual math.
How to Reconstitute PT-141
Compounded PT-141 comes as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before injection. This process is standard for peptide vials. Vyleesi auto-injectors are pre-filled and do not require reconstitution.
Supplies Needed:
- PT-141 lyophilized vial (typically 10 mg)
- Bacteriostatic water (BAC water) — contains 0.9% benzyl alcohol as preservative
- Insulin syringes (29–31 gauge, 0.5 mL or 1 mL) for injection
- Alcohol swabs (70% isopropyl alcohol)
- Clean, flat workspace
- Optional: larger syringe (1–3 mL) for drawing bacteriostatic water if using a separate drawing needle
Steps
Wash Hands & Prepare Workspace
Wash hands thoroughly with soap and water. Lay out supplies on a clean surface: PT-141 vial, bacteriostatic water, insulin syringe, and alcohol swabs.
Remove the Vial Caps
Flip off the plastic caps from both the PT-141 vial and the bacteriostatic water vial. Swab both rubber stoppers with alcohol pads and let them air-dry for 10–15 seconds.
Draw Bacteriostatic Water
Using a fresh insulin syringe, draw your desired volume of bacteriostatic water. For a 10 mg vial, 2 mL is standard (yields 5 mg/mL — 1.75 mg = 35 units).
Add Water to the Peptide Calculator Vial
Insert the needle into the PT-141 vial through the rubber stopper. Angle the needle so the water runs down the inside glass wall — never squirt directly onto the powder cake. Release the plunger slowly.
Dissolve Gently
Remove the syringe. Let the vial sit for 1–2 minutes, then gently swirl or roll between your palms until the powder is fully dissolved. The solution should be clear and colorless. Never shake.
Label & Refrigerate
Write the reconstitution date and concentration on the vial. Store refrigerated at 2–8°C. Use within 28–30 days.
Storage
- Unreconstituted (powder): Store refrigerated (2–8°C) for maximum shelf life; room temperature is acceptable for short periods (weeks) but reduces potency over time
- Reconstituted (in bacteriostatic water): Must be refrigerated at 2–8°C; use within 28–30 days
- Do not freeze: Freezing reconstituted PT-141 can damage the peptide structure through ice crystal formation
- Protect from light and heat — keep the vial in its box or wrapped in foil, away from direct sunlight and temperatures above 25°C
For a detailed visual walkthrough, see our Reconstitution Guide.
PT-141 Injection Guide
Subcutaneous (SubQ) Injection — Step by Step
Wash Hands
Wash hands thoroughly with soap and water. Prepare a clean workspace with your syringe, alcohol swab, and reconstituted PT-141 vial.
Swab the Vial Stopper
Wipe the rubber stopper of the PT-141 vial with an alcohol swab. Let it air-dry for 10–15 seconds.
Draw Your Dose
Pull back the plunger to draw air equal to your dose volume. Insert the needle into the vial, push in the air, invert the vial, and slowly draw out your calculated dose. Tap out any air bubbles.
Choose the Injection Site
The lower abdomen is the standard injection site for PT-141. Choose a spot at least 2 inches (5 cm) from the navel. Rotate injection sites to avoid irritation.
Clean the Injection Site
Swab the chosen injection site with a fresh alcohol pad. Allow to air-dry completely before injecting.
Inject
Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 45-degree angle into the pinched skin fold. Push the plunger slowly and steadily. Withdraw the needle and apply light pressure with the alcohol swab if needed.
Dispose Safely
Place the used syringe immediately into a sharps container. Never recap or reuse needles.
Timing
- Women: Inject at least 45 minutes before anticipated sexual activity. Onset is typically 45–60 minutes.
- Men: Inject 1–2 hours before anticipated activity. Onset is slower in men than in women.
- Do not re-dose within 24 hours regardless of whether effects are perceived.
Why Frequency Limits?
PT-141's frequency restrictions are not arbitrary — they are based on specific safety and pharmacological considerations identified during clinical trials. Understanding why these limits exist helps users take PT-141 responsibly.
- Blood pressure effects — PT-141 can cause transient increases in systolic and diastolic blood pressure. Frequent dosing increases the cumulative cardiovascular burden, particularly in individuals with pre-existing hypertension.
- Nausea (frequency-dependent) — Nausea affects approximately 40% of users and is the most common side effect. While individual episodes often improve with repeated use, dosing too frequently within a short period can worsen nausea severity.
- MC receptor desensitization — Repeated activation of melanocortin-4 receptors (MC4R) can lead to receptor downregulation, reducing the peptide’s efficacy over time. Spacing doses allows receptor recovery and maintains responsiveness.
- Hyperpigmentation risk — PT-141 retains some activity at MC1R, the melanocortin receptor responsible for skin pigmentation. Frequent use increases the risk of focal hyperpigmentation (darkening of the face, gums, or other areas).
PT-141 Stacking Protocols
PT-141 is an as-needed peptide, not a daily protocol, which limits its stacking potential compared to peptides like BPC-157 or TB-500. The primary stack of clinical relevance combines PT-141 with PDE5 inhibitors for men with erectile dysfunction.
PT-141 + PDE5 Inhibitors (Men) — Central + Peripheral Mechanism
Combining PT-141 with a PDE5 inhibitor (sildenafil / Viagra or tadalafil / Cialis) addresses sexual dysfunction from two complementary angles: PT-141 works centrally in the brain to enhance desire and arousal, while PDE5 inhibitors work peripherally to increase blood flow. This combination has been studied in men who did not respond adequately to PDE5 inhibitors alone.
| Compound | Dose | Route | Purpose |
|---|---|---|---|
| PT-141 | 1.0–2.0 mg | SubQ injection | Central MC4R activation — enhances desire and arousal |
| Sildenafil (Viagra) | 25–50 mg | Oral | Peripheral PDE5 inhibition — increases blood flow |
Why PT-141 Doesn't Stack with Most Peptides
Unlike daily peptides that run in multi-week cycles, PT-141 is used only as needed with strict frequency limits. It does not synergize meaningfully with healing peptides (BPC-157, TB-500), growth hormone secretagogues (Ipamorelin, CJC-1295), or cosmetic peptides. PT-141 serves a specific, acute purpose and is best used as a standalone peptide for its intended indication.
Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.
Safety, Side Effects & Contraindications
PT-141's safety profile is well-characterized from clinical trials involving over 1,200 participants. As an FDA-approved drug (for premenopausal women with HSDD), it has undergone more rigorous safety evaluation than most research peptides.
Very Common (>10% of users)
- Nausea — ~40% of users; the most common side effect. Peaks 1–2 hours after injection and typically resolves within a few hours. Tends to decrease with repeated use.
- Flushing — ~20% of users; temporary warmth and redness of the face, neck, or chest.
- Headache — ~11% of users; usually mild and self-resolving.
Common (1–10%)
- Injection site reactions (redness, bruising, minor swelling)
- Hot flash
Less Common (<1%)
- Transient blood pressure elevation — monitor if you have hypertension or cardiovascular risk factors
- Skin darkening (hyperpigmentation) — more likely with frequent or prolonged use; less pronounced than with Melanotan II
- Focal hyperpigmentation — darkening of specific areas (face, gums); reversible upon discontinuation in most cases
Managing Nausea
- Light snack — eat a small, bland meal 30–60 minutes before injection to reduce gastric irritation
- Ondansetron (Zofran) — 4–8 mg taken 30 minutes before PT-141 injection can significantly reduce nausea. Available by prescription.
- Start at a lower dose — if nausea is severe at 1.75 mg, try 1.0 mg to assess tolerance before increasing
- Nausea decreases with repeated use — most users report that nausea severity diminishes after the first few doses as the body adapts
Contraindications
- Uncontrolled hypertension — PT-141 can cause transient blood pressure increases. Do not use if blood pressure is not adequately controlled.
- Cardiovascular disease — patients with known cardiovascular disease should consult their cardiologist before use due to blood pressure effects.
- Pregnancy (Category X) — PT-141 is contraindicated in pregnancy. Women of childbearing potential should use effective contraception.
- Hepatic impairment — PT-141 has not been adequately studied in patients with significant liver disease. Avoid use or consult a specialist.
Drug Interactions
- Naltrexone — contraindicated. Naltrexone (an opioid antagonist) can reduce the efficacy of PT-141 and may alter its safety profile. Do not combine.
- Blood pressure medications — PT-141 can cause transient BP increases. If taking antihypertensives, monitor blood pressure closely and inform your prescriber.
- PDE5 inhibitors (Viagra, Cialis) — can be combined under medical supervision but both affect blood pressure. Use reduced PDE5 inhibitor doses.
Common PT-141 Dosing Mistakes
Avoid these common errors to use PT-141 safely and effectively:
Frequently Asked Questions
Key Takeaways
- FDA-approved (Vyleesi) for premenopausal women with hypoactive sexual desire disorder (HSDD) — one of the few peptides with full FDA approval
- Standard dose: 1.75 mg SubQ, injected at least 45 minutes before anticipated sexual activity
- Maximum 8 doses per month — no more than 1 dose per 24 hours. This is a safety boundary, not a target.
- Works centrally in the brain through melanocortin-4 receptors (MC4R) in the hypothalamus — fundamentally different from Viagra/Cialis
- ~40% nausea rate — the most common side effect. Manage with a light snack, lower starting dose, or ondansetron (Zofran). Nausea decreases with repeated use.
- Gender-specific protocols — women: 1.75 mg, 45-minute onset; men: 1.0–2.0 mg (off-label), 1–2 hour onset
- Not a daily peptide — strictly as-needed dosing only. Daily use leads to receptor desensitization and increased side effects.
- Derived from Melanotan II but structurally modified to focus on sexual function with reduced tanning effects
- Contraindicated with naltrexone and in uncontrolled hypertension, cardiovascular disease, and pregnancy (Category X)
This article is for educational and informational purposes only. See our Disclaimer.
References
- Kingsberg SA, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstet Gynecol. 2019;134(5):899-908. (RECONNECT trials) PubMed
- Diamond LE, et al. “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.” J Sex Med. 2006;3(4):628-638. PubMed
- Rosen RC, et al. “Bremelanotide: a new pharmacotherapy for hypoactive sexual desire disorder.” Expert Opin Investig Drugs. 2017;26(9):1049-1057.
- AMAG Pharmaceuticals. “Vyleesi (bremelanotide injection) Prescribing Information.” FDA.gov. 2019.
- Molinoff PB, et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Ann N Y Acad Sci. 2003;994:96-102. PubMed
Next Steps
Continue your research with these resources.
Kisspeptin Profile
Explore Kisspeptin, another peptide researched for sexual health and reproductive function.
Read ProfileDosage Calculator
Calculate your exact PT-141 dose based on vial size and reconstitution volume.
Open CalculatorPeptide Directory
Browse all peptides with research summaries and dosing data.
View Directory